News · 26 weeks62+100%
2026-03-012026-08-23
Mix2690d
- Other11(42%)
- SEC Filings7(27%)
- Insider7(27%)
- M&A1(4%)
Latest news
25 items- PRLabcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care SettingsElecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's diseaseIntended for individuals 55 and older with signs, symptoms or complaints of cognitive declineBURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identif
- INSIDERDirector Anderson Kerrii B sold $954,060 worth of shares (3,000 units at $318.02) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 6,563 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community HealthCollaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centers (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support curren
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Host Investor Day on September 10, 2026BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, Executive Vice President and CFO Julia Wang and other members of the executive leadership team will discuss the company's go-forward strategy, capital deployment priorities and long-term financial outlook. Presentations will be followed by a Q&A session.A live webcast of the event will be available through the Labcorp Investor Relations website beg
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- INSIDERPresident & CEO Schechter Adam H sold $1,495,808 worth of shares (4,669 units at $320.37) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 102,565 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced MelanomaLabcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapiesSupports access to targeted treatment options for the deadliest form of skin cancerBURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
- INSIDEREVP, Chief Marketing Officer Summy Amy B. sold $283,428 worth of shares (924 units at $306.74), decreasing direct ownership by 12% to 6,956 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- SECSEC Form 10-Q filed by Labcorp Holdings Inc.10-Q - LABCORP HOLDINGS INC. (0000920148) (Filer)
- INSIDERSVP, Chief Accounting Officer Wilkinson Peter J sold $439,107 worth of shares (1,420 units at $309.23) and exercised 1,338 shares at a strike of $209.25, decreasing direct ownership by 4% to 1,770 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate CancerFirst FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 GuidanceResults from operations for second quarter 2026 versus second quarter 2025:Revenue: $3.73 billion vs. $3.53 billion, up 5.8%Diluted EPS: $3.64 vs. $2.84, up 28.5%Adjusted EPS: $4.99 vs. $4.35, up 14.9%Raised full-year enterprise revenue growth and adjusted EPS guidance:Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpointAdjusted EPS range of $18.10 to $18.55; up 30 cents at the midpointAnnounced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billionAdvanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selecti
- PRLabcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk TestingNew offering analyzes 163 genes linked to more than 100 medically actionable conditionsIncludes genetic counseling support to help consumers understand results and take informed next stepsConsumers can now access biomarker and hereditary genetic testing from a single source through Labcorp OnDemandBURLINGTON, N.C., July 27, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of Marker by Labcorp™ Genetic Health Panel, a new offering designed to help consumers better understand inherited risks associated with more than 100 medically actionable health conditions. Available through Labcorp OnDemand, the panel an
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- INSIDEREVP, Chief Legal Officer Kyle Kathryn W converted options into 256 shares, covered exercise/tax liability with 73 shares and sold $26,329 worth of shares (92 units at $286.19) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 3,904 units (SEC Form 4) (for withholding tax)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDEREVP and President, Diagnostics Vaughn Bryan T covered exercise/tax liability with 93 shares, sold $66,968 worth of shares (234 units at $286.19) as part of a pre-agreed trading plan and converted options into 327 shares (SEC Form 4) (for withholding tax)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.
- PRLabcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening TestFirst FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomasDesigned to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN)BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food a
- INSIDEREVP, Chief Legal Officer Kyle Kathryn W sold $201,084 worth of shares (762 units at $263.89) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 3,813 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal CancerCollaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family membersResearch will also assess the clinical impact of broader genetic testing in colorectal cancer careBURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the
- PRLabcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side EffectsNew pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatmentBURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
LH FAQ
7 questionsWhat does Labcorp Holdings Inc. do?
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based...Where does LH stock trade?
Labcorp Holdings Inc. (LH) is listed on NYSE.What sector and industry is LH in?
Labcorp Holdings Inc. operates in the Health Care sector, Medical Specialities industry.Does LH pay a dividend?
Yes. LH's next ex-dividend date is 2026-08-28 with a declared cash dividend of $0.72 per share, payable 2026-09-11.What are analysts saying about LH?
Labcorp Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Hold on 2025-07-10.What companies are similar to LH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare LH side-by-side with any of them on Quantisnow.How can I track LH on Quantisnow?
Quantisnow aggregates Labcorp Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LH to receive live email and push alerts on every new disclosure.